Studies show that patients with difficult-to-treat axial spondyloarthritis had more disease activity and greater peripheral involvement, with extra musculoskeletal manifestations and fibromyalgia. The ACR Convergence 2024 session on Difficult-to-Manage Spondyloarthritis will focus on patients for whom first- and second-line therapies have failed or who have persistent extra-axial manifestations of disease despite these treatment options. The…
Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.
In a phase 3 trial, treatment with VX-548 led to statistically and clinically significant improvements in pain compared with placebo.
Pain management can involve more than active pharmacologic treatment. During a session at ACR Convergence 2023, experts addressed the benefits of patient self-management for pain, how it works with clinical care and the role of technology.
SAN DIEGO—Pain is one of the most common symptoms of rheumatic disease, and this session at ACR Convergence 2023 was dedicated to understanding recent research concerning the relationship between pain and inflammation.
Regular movement is crucial for everyone, but patients with rheumatic disease may feel overwhelmed about starting and maintaining a routine. Here’s how physical and occupational therapists can help patients establish and reach movement goals, while improving their pain management and overall health.
Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.
A study from Haibel et al. in patients with chronic knee arthritis found intra-articular morphine did not lead to a significant, short-term reduction in pain compared with placebo and proved inferior to treatment with intra-articular triamcinolone.
Pain is more than nociception, and pain management is more than medication. Delia Chiaramonte, MD, provided insights into how rheumatologists can help their patients ease and manage chronic pain.
NEW YORK (Reuters Health)—Oral synthetic cannabis products that have a high tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio, as well as extracted cannabis products with comparable THC-to-CBD ratios, may provide moderate, short-term improvements in chronic pain, a large systematic review of relevant research suggests.1 However, these products are also associated with higher risks for side effects,…